Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 6/2017

Open Access 01-06-2017 | Special Article

Consensus guidelines for diagnosis, treatment and follow-up of patients with pancreatic cancer in Spain

Authors: M. Hidalgo, R. Álvarez, J. Gallego, C. Guillén-Ponce, B. Laquente, T. Macarulla, A. Muñoz, M. Salgado, R. Vera, J. Adeva, I. Alés, S. Arévalo, J. Blázquez, A. Calsina, A. Carmona, E. de Madaria, R. Díaz, L. Díez, T. Fernández, B. G. de Paredes, M. E. Gallardo, I. González, O. Hernando, P. Jiménez, A. López, C. López, F. López-Ríos, E. Martín, J. Martínez, A. Martínez, J. Montans, R. Pazo, J. C. Plaza, I. Peiró, J. J. Reina, A. Sanjuanbenito, R. Yaya, Alfredo Carrato

Published in: Clinical and Translational Oncology | Issue 6/2017

Login to get access

Abstract

The management of patients with pancreatic cancer has advanced over the last few years. We convey a multidisciplinary group of experts in an attempt to stablish practical guidelines for the diagnoses, staging and management of these patients. This paper summarizes the main conclusions of the working group. Patients with suspected pancreatic ductal adenocarcinoma should be rapidly evaluated and referred to high-volume centers. Multidisciplinary supervision is critical for proper diagnoses, staging and to frame a treatment plan. Surgical resection together with chemotherapy offers the highest chance for cure in early stage disease. Patients with advanced disease should be classified in treatment groups to guide systemic treatment. New chemotherapeutic regimens have resulted in improved survival. Symptomatic management is critical in this disease. Enrollment in a clinical trial is, in general, recommended.
Literature
1.
2.
GLOBOCAN. European age-standardised rates calculated by the statistical information team at cancer research UK, 2011 using data from GLOBOCAN 2008 v1.2, IARC, version 1.2. http://​globocan.​iarc.​fr. Accessed May 2016.
3.
Hidalgo M, Cascinu S, Kleeff J, Labianca R, Löhr JM, Neoptolemos J, et al. Addressing the challenges of pancreatic cancer: future directions for improving outcomes. Pancreatology. 2015;15:8–18.PubMedCrossRef
4.
Ko AH. Pancreatic cancer and the possibility of long-term survival. A glimmer of hope. JAMA Oncol. 2016;2:380–1.PubMedCrossRef
5.
Dykewicz CA. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clin Infect Dis. 2001;33:139–44.PubMedCrossRef
6.
Porta M, Fabregat X, Malats N, Guarner L, Carrato A, de Miguel A, et al. Exocrine pancreatic cancer: symptoms at presentation and their relation to tumour site and stage. Clin Trans Oncol. 2005;7:189–97.CrossRef
7.
Ducreux M, Cuhna AS, Caramella C, Hollebecque A, Burtin P, Goere D, et al. Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26:56–68.CrossRef
8.
Hart PA, Kamada P, Rabe KG, Srinivasan S, Basu A, Aggarwal G, et al. Weight loss precedes cancer-specific symptoms in pancreatic cancer-associated diabetes mellitus. Pancreas. 2011;40:768–72.PubMedPubMedCentralCrossRef
9.
Chari ST, Leibson CL, Rabe KG, Ransom J, de Andrade M, Petersen GM. Probability of pancreatic cancer following diabetes: a population-based study. Gastroenterology. 2005;129:504–11.PubMedPubMedCentralCrossRef
10.
Ben Q, Xu M, Ning X, Liu J, Hong S, Huang W, et al. Diabetes mellitus and risk of pancreatic cancer: a meta-analysis of cohort studies. Eur J Cancer. 2011;47:1928–37.PubMedCrossRef
11.
Canto MI, Harink F, Hruban RH, Offerhaus GJ, Poley JW, Kamel I, et al. International Cancer of the pancreas screening consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut. 2013;62:339–47.PubMedCrossRef
12.
Guillen-Ponce C, Mocci E, Earl J, Márquez M, Solera J, Salazar-López MT, et al. PANGEN-FAM: Spanish Registry of Hereditary Pancreatic Cancer. Eur J Cancer. 2015;51:1911–7.PubMedCrossRef
13.
Canto MI, Goggins M, Hruban RH, Petersen GM, Giardiello FM, Yeo C, et al. Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study. Clin Gastroenterol Hepatol. 2006;4:766–81.PubMedCrossRef
14.
Poley JW, Kluijt I, Gouma DJ, Harinck F, Wagner A, Aalfs C, et al. The yield of first-time endoscopic ultrasonography in screening individuals at a high risk of developing pancreatic cancer. Am J Gastroenterol. 2009;104:2175–81.PubMedCrossRef
15.
Canto MI, Hruban RH, Fishman EK, Kamel IR, Schulick R, Zhang Z, et al. American Cancer of the Pancreas Screening (CAPS) Consortium. Frequent detection of pancreatic lesions in asymptomatic high-risk individuals. Gastroenterology. 2012;142:796–804.PubMedPubMedCentralCrossRef
16.
Humphris JL, Johns A, Simpson H, Cowley MJ, Pajic M, Chang DK, et al. Clinical and pathologic features of familial pancreatic cancer. Cancer. 2014;120:3669–75.PubMedCrossRef
17.
Miura F, Takada T, Amano H, Yoshida M, Furui S, Takeshita K, et al. Diagnosis of pancreatic cancer. HPB (Oxford). 2006;8:337–42.CrossRef
18.
Al-Hawary MM, Francis IR, Chari ST, Fishman EK, Hough DM, Lu DS, et al. Pancreatic ductal adenocarcinoma radiology reporting template: consensus statement of the Society of Abdominal Radiology and the American Pancreatic Association. Radiology. 2014;270:248–60.PubMedCrossRef
19.
Fernández-del Castill. Clinical manifestations, diagnosis, and staging of exocrine pancreatic cancer. 2015. (Up To Date: August journal).
20.
Nawaz H, Fan CY, Kloke J, Khalid A, McGrath K, Landsittel D, Papachristou GI, et al. Performance characteristics of endoscopic ultrasound in the staging of pancreatic cancer: a meta-analysis. JOP. 2013;14:484–97.PubMedPubMedCentral
21.
Asbun HJ, Conlon K, Fernandez-Cruz L, Friess H, Shrikhande SV, Adham M, et al. When to perform a pancreatoduodenectomy in the absence of positive histology? A consensus statement by the International Study Group of Pancreatic Surgery. Surgery. 2014;155:887–92.PubMedCrossRef
22.
Munroe CA, Fehmi SM, Savides TJ. Endoscopic ultrasound in the diagnosis of pancreatic cancer. Expert Opin Med Diagn. 2013;7:25–35.PubMedCrossRef
23.
Morris-Stiff G, Taylor MA. CA 19.9 and pancreatic cancer: is it really that good? J Gastrointest Oncol. 2012;3:88–389.PubMedPubMedCentral
24.
Cwik G, Wallner G, Skoczylas T, Ciechanski A, Zinkiewicz K. Cancer antigens 19-9 and 125 in the differential diagnosis of pancreatic mass lesions. Arch Surg. 2006;141:968.PubMedCrossRef
25.
Kondo N, Murakami Y, Uemura K, Hayashidani Y, Sudo T, Hashimoto Y, et al. Prognostic impact of perioperatory serum CA 19.9 levels in patients with resectable pancreatic cancer. Ann Surg Oncol. 2010;17:2321.PubMedCrossRef
26.
Humphris JL, Chang DK, Al Johns, Scarlett CJ, Pajic M, Jones MD, et al. The prognostic and predictive value of serum CA 19.9 in pancreatic cancer. Ann Oncol. 2012;23:1713.PubMedPubMedCentralCrossRef
27.
Kim JE, Lee KT, Lee JK, Paik SW, Rhee JC, Choi KW, et al. Clinical usefulness of carbohydrate antigen 19.9 as a screening test for pancreatic cancer in an asymptomatic population. J Gastroenterol Hepatol. 2004;19:182.PubMedCrossRef
28.
Yu J, Blackford AL, Molin M, Wolfgang CL, Goggins M. Time to progression of pancreatic ductal adenocarcinoma from low-to-high tumour stages. Gut. 2015;0:1–7.
29.
Nishida K, Kaneko T, Yoneda M, Nakagawa S, Ishikawa T, Yamane E, et al. Doubling time of serum CA 19-9 in the clinical course of patients with pancreatic cancer and its significant association with prognosis. J Surg Oncol. 1999;71:140–6.PubMedCrossRef
30.
31.
32.
33.
34.
Chen YG, Pan HH, Dai MS, Lin C, Lu CS, Su SL, et al. Impact of comorbidity and age on determinants therapeutic strategies in advanced pancreatic head cancer patients with obstructive jaundices. Medicine (Baltimore). 2015;94:e1298.CrossRef
35.
Von Hoff DD, Ervin T, Arena FP, Chiorean G, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691–703.CrossRef
36.
Gillen S, Schuster T, Meyer Zum Büschenfelde C, Friess H, Kleef J. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med. 2010;7:e1000267.PubMedPubMedCentralCrossRef
37.
Assifi MM, Lu X, Eibl G, Reber HA, Li G, Hines OJ. Neoadjuvant therapy in pancreatic adenocarcinoma: a meta-analysis of phase II trials. Surgery. 2011;150:466–73.PubMedPubMedCentralCrossRef
38.
Andriulli A, Festa V, Botteri E, Valvano MR, Koch M, Bassi C, Maisonneuve P, et al. Neoadjuvant/preoperative gemcitabine for patients with localized pancreatic cancer: a meta-analysis of prospective studies. Ann Surg Oncol. 2012;19:1644–62.PubMedCrossRef
39.
Christians K, Tsai S, Mahmoud A, Ritch P, Thomas JP, Wiebe L, et al. Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm? Oncologist. 2014;19:266–74.PubMedPubMedCentralCrossRef
40.
Mahaseth H, Brutcher E, Kauh J, Hawk N, Kim S, Chen Z, et al. Modified FOLFIRINOX regimen with improved safety and maintained efficacy in pancreatic adenocarcinoma. Pancreas. 2013;42:1311–5.PubMedCrossRef
41.
Peddi PF, Lubner S, McWilliams R, Tan BR, Picus J, Sorscher SM, et al. Multi-institutional experience with FOLFIRINOX in pancreatic adenocarcinoma. JOP. 2012;13:497–501.PubMed
42.
Hosein PJ, Macintyre J, Kawamura C, Maldonado JC, Ernani V, Loaiza-Bonilla A, et al. A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma. BMC Cancer. 2012;12:199.PubMedPubMedCentralCrossRef
43.
Mellon EA, Hoffe SE, Springett GM, Frakes JM, Strom TJ, Hodul PJ, et al. Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma. Acta Oncol. 2015;54:585–979.CrossRef
44.
Marthey L, Sa-Cunha A, Blanc JF, Gauthier M, Cueff A, Francois E, et al. FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational cohort. Ann Surg Oncol. 2015;22:295–301.PubMedCrossRef
45.
Alvarez R, Musteanu M, Garcia-Garcia E, López-Casas PP, Megias D, Guerra C, et al. Stromal disrupting effects of nab-paclitaxel in pancreatic cancer. Br J Cancer. 2013;109:926–33.PubMedPubMedCentralCrossRef
46.
Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817–25.PubMedCrossRef
47.
Katz MH, Fleming JB, Bhosale P, Varadhachary G, Je Lee, Wolff R, et al. Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer. 2012;118:5749–56.PubMedCrossRef
48.
Tzeng CW, Balachandran A, Ahmad M, et al. Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer. HPB (Oxford). 2014;16:430–8.CrossRef
49.
Katz MH, Varadhachary GR, Fleming JB, Wolff RA, Lee JE, Pisters PWT, et al. Serum CA 19-9 as a marker of resectability and survival in patients with potentially resectable pancreatic cancer treated with neoadjuvant chemoradiation. Ann Surg Oncol. 2010;17:1794–801.PubMedPubMedCentralCrossRef
50.
Tamm EP, Balachandran A, Bhosale PR, Katz MH, Fleming JB, Lee JH, et al. Imaging of pancreatic adenocarcinoma: update on staging/resectability. Radiol Clin North Am. 2012;50:407–28.PubMedCrossRef
51.
Bockhorn M, Uzunoglu FG, Adham M, Imrie C, Milicevic M, Sandberg AA, et al. Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS). Surgery. 2014;155:977–88.PubMedCrossRef
52.
Callery MP, Chang KJ, Fishman EK, Talamonti MS, Traverso W, Linehan DC, et al. Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann Surg Oncol. 2009;16:1727–33.PubMedCrossRef
53.
Varadhachary GR, Tamm EP, Abbruzzese JL, Xiong HQ, Crane CH, Wang H, et al. Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol. 2006;13:1035–46.PubMedCrossRef
54.
Katz MH, Marsh R, Herman JM, Shi Q, Collison E, Venook AP, et al. Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design. Ann Surg Oncol. 2013;20:2787–95.PubMedCrossRef
55.
Evans DB, Farnell MB, Lillemoe KD, Vollmer C Jr, Strasberg SM, Schulick RD. Surgical treatment of resectable and borderline resectable pancreas cancer: expert consensus statement. Ann Surg Oncol. 2009;16:1736–44.PubMedCrossRef
56.
Braga M, Capretti G, Pecorelli N, Balzano G, Doglioni C, Ariotti R, et al. A prognostic score to predict major complications after pancreaticoduodenectomy. Ann Surg. 2011;254:702–8.PubMedCrossRef
57.
Uzunoglu FG, Reeh M, Vettorazzi E, Ruschke T, Hannah P, Nentwich MF, et al. Preoperative Pancreatic Resection (PREPARE) score: a prospective multicenter-based morbidity risk score. Ann Surg. 2014;260:857–64.PubMedCrossRef
58.
Ragulin-Coyne E, Carroll JE, Smith JK, Witkowski ER, Ng SC, Shah SA, et al. Perioperative mortality after pancreatectomy: a risk score to aid decision-making. Surgery. 2012;152(3 Suppl. 1):S120–7.PubMedCrossRef
59.
60.
Hartwig W, Vollmer CM, Fingerhut A, Yeo CJ, Neoptolemos JP, Adham M, et al. Extended pancreatectomy in pancreatic ductal adenocarcinoma: definition and consensus of the International Study Group for Pancreatic Surgery (ISGPS). Surgery. 2014;156:1–14.PubMedCrossRef
61.
Hartwig W, Gluth A, Hinz U, Bergmann F, Spronk PE, Hackert T, et al. Total pancreatectomy for primary pancreatic neoplasms: renaissance of an unpopular operation. Ann Surg. 2015;261:537–46.PubMedCrossRef
62.
Boggi U, Amorese G, Vistoli F, Caniglia F, De Lio N, Perrone V, et al. Laparoscopic pancreaticoduodenectomy: a systematic literature review. Surg Endosc. 2015;29:9–23.PubMedCrossRef
63.
Stafford AT, Walsh M. Robotic surgery of the pancreas: the current state of the art. J Surg Oncol. 2015;112:289–94.PubMedCrossRef
64.
Roder JD, Stein HJ, Siewert JR. Carcinoma of the periampullary region: who benefits from portal vein resection. Am J Surg. 1996;171:170–4.PubMedCrossRef
65.
Siriwardana HP, Siriwardena AK. Systematic review of outcome of synchronous portal-superior mesenteric vein resection during pancreatectomy for cancer. Br J Surg. 2006;93:662–73.PubMedCrossRef
66.
Oettle H, Neuhaus P, Hochhaus A, Hartmann JT, Gellert K, Ridwelski K, et al. Adjuvant chemotherapy with gemcitabine and longterm outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013;310:1473–81.PubMedCrossRef
67.
Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection. JAMA. 2010;304:1073–112.PubMedCrossRef
68.
Alamo JM, Marín LM, Suárez G, et al. Improving outcomes in pancreatic cancer: key points in perioperative management. World J Gastroenterol. 2014;20:14237–45.PubMedPubMedCentralCrossRef
69.
Duelge K, Krepline AN, Mahmoud A (2014) Survival benefit of adjuvant therapy for resectable pancreatic cancer (RPC) patients treated with neoadjuvant Therapy. In: Oncology 67th annual Cancer Symposium of the Society of Surgical Oncology Phoenix. Annals of Surgical Oncology; Poster P173.
70.
Roland CL, Katz MH, Tzeng CD, Lin H, Varadhachary GR, Shroff R, et al. The addition of postoperative chemotherapy is associated with improved survival in patients with pancreatic cancer treated with preoperative therapy. Ann Surg Oncol. 2015. [Epub ahead of print].
71.
Cascinu S, Falconi M, Valentini V, Jelic S, on behalf of the ESMO Guidelines Working Group. Pancreatic cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21:v55–8.PubMedCrossRef
72.
Berger AC, Garcia M, Hoffman JP, Regine WF, Abrams RA, Safran H, et al. Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704. J Clin Oncol. 2008;26:5918–22.PubMedPubMedCentralCrossRef
73.
Yang GY, Malik NK, Chandrasekhar R, Ma WW, Flaherty L, Iyer R, et al. Change in CA 19-9 levels after chemoradiotherapy predicts survival in patients with locally advanced unresectable pancreatic cancer. J Gastrointest Oncol. 2013;4:361–9.PubMedPubMedCentral
74.
Neoptolemos JP, Stocken DD, Friess H, Bassic C, Dunn JA, Hickey H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350:1200–10.PubMedCrossRef
75.
Liao WC, Chien KL, Lin YL, Wu MS, Lin JT, Wang HP, et al. Adjuvant treatments for resected pancreatic adenocarcinoma: a systematic review and network meta-analysis. Lancet Oncol. 2013;14:1095–103.PubMedCrossRef
76.
Neoptolemos JP, Palmer D, Ghaneh P, Valle JW, Cunningham D, Wadsley J, et al. ESPAC-4: A multicenter, international, open-label randomized controlled phase III trial of adjuvant combination chemotherapy of gemcitabine (GEM) and capecitabine (CAP) versus monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcinoma. J Clin Oncol. 2016;34 (abstr LBA4006).
77.
Gastrointestinal Tumor Study Group. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer. 1987;59:2006–10.CrossRef
78.
Klinkenbijil JH, Jeekel J, Sahmoud T. Adjuvant radiotherapy and 5-fluoruracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg. 1999;230:776–82.CrossRef
79.
Regine WF, Winter KA, Abrams RA. Fluoruracil vs gemcitabine chemotherapy before and after fluoruracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA. 2008;299:1019–26.PubMedCrossRef
80.
Corsini MM, Miller RC, Haddock MG, Donohue JH. Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: the Mayo Clinic experience (1975–2005). J Clin Oncol. 2008;26:3511–6.PubMedCrossRef
81.
Herman JM, Swartz MJ, Hsu CC. Analysis of fluoruracil based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large prospectively collected database at the Johns Hopkins Hospital. J Clin Oncol. 2008;26:3503–10.PubMedPubMedCentralCrossRef
82.
Hazard L, Tward JD, Szabo A. Radiation Therapy is associated with improved survival in patients pancreatic adenocarcinoma: results of a study form the Surveillance, Epidemiology and End Results (SEER) registry data. Cancer. 2007;110:2191–201.PubMedCrossRef
83.
Witkowski ER, Smith JK, Ragulin-Coyne E, Ng SC, Shah SA, Tseing JF. Is it worth looking? Abdominal imaging after pancreatic cancer resection: a national study. J Gastrointest Surg. 2012;16:121–8.PubMedCrossRef
84.
Sheffield KM, Crowell KT, Lin YL, Djukom C, Goodwin JS, Riall TS. Surveillance of pancreatic cancer patients after surgical resection. Ann Surg Oncol. 2012;19:1670–7.PubMedCrossRef
85.
Benavides M, Abad A, Ales I, Carrato A, Díaz Rubio E, Gallego J, et al. TTD consensus document on the diagnosis and management of exocrine pancreatic cancer. Clin Transl Oncol. 2014;16:865–78.PubMedCrossRef
86.
Faris JE, Blaszkowsky LS, McDermott S, Guimaraes AR, Szymonifka J, Huynh MA, et al. FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience. Oncologist. 2013;18:543–8.PubMedPubMedCentralCrossRef
87.
Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403–13.PubMedCrossRef
88.
Hammel P, Huguet F, Van Laethem JL, Goldstein D, Glimelius B, Artru P, et al. Comparison of Comparison of chemoradiotherapy (CRT) and chemotherapy (CT) in patients with a locally advanced pancreatic cancer (LAPC) controlled after 4 months of gemcitabine with or without erlotinib: final results of the international phase III LAP 07 study. J Clin Oncol. 2013;31:LBA4003.CrossRef
89.
Mukherjee S, Hurt C, Griffiths G, Bridgewater JA, Crosby T, Falk S, et al. SCALOP: Results of a randomized phase II study of induction chemotherapy followed by gemcitabine (G) or capecitabine (Cap) based chemoradiation (CRT) in locally advanced pancreatic cancer (LANPC). J Clin Oncol. 2013;31:LBA146.CrossRef
90.
Peixoto RD, Ho M, Renouf DJ, Lim HJ, Gill S, Ruan JY, et al. Eligibility of Metastatic Pancreatic Cancer Patients for First-Line Palliative Intent nab-Paclitaxel Plus Gemcitabine Versus FOLFIRINOX. Am J Clin Oncol. 2015. [Epub ahead of print].
91.
Thota R, Pauff JM, Berlin JD. Treatment of metastatic pancreatic adenocarcinoma: a review. Oncology (Williston Park). 2014;28(1):70–4.
92.
Rahma OE, Duffy A, Liewehr DJ, Steinberg SM, Greten TF, et al. Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials. Ann Oncol. 2013;24:1972–9.PubMedPubMedCentralCrossRef
93.
Oettle H, Riess H, Stieler JM, Heil G, Schwaner I, Seraphin J, et al. Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 Trial. J Clin Oncol. 2014;32:2423–9.PubMedCrossRef
94.
Gill S, Ko YJ, Cripps C, Beaudoin A, Dhesy-Thind SK, Zulfigar M, et al. PANCREOX: a randomized phase 3 study of 5FU/LV with or without oxaliplatin for second-line advanced pancreatic cancer (APC) in patients (pts) who have received gemcitabine (GEM)-based chemotherapy (CT). J Clin Oncol. 2014;32(5s):A4022.
95.
Wang-Gillam A, Li CP, Bodoky G, Dean A, Shan YS, Jameson G, et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet. 2016;387:545–57.PubMedCrossRef
96.
Bertocchi P, Abeni C, Meriggi F, Rota L, Rizzi A, Di Biasi B, et al. Gemcitabine plus nab-paclitaxel as second-line and beyond treatment for metastatic pancreatic cancer: a single institution retrospective analysis. Rev Recent Clin Trials. 2015;10:142–5.PubMedCrossRef
97.
Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol. 2006;24:5313–27.PubMedCrossRef
98.
Stark A, Hines OJ. Endoscopic and operative palliation strategies for pancreatic ductal adenocarcinoma. Semin Oncol. 2015;42:163–76.PubMedCrossRef
99.
Sarfeh IJ, Rypins EB, Jakowatz JG. A prospective, randomized clinical investigation of cholecystoenterostomy and choledochoenterostomy. Am Surg. 1989;55:55–60.
100.
Glazer ES, Hornbrook MC. A meta-analysis of randomized trials: immediate stent replacement vs surgical bypass in the palliative management of malignant biliary obstruction. J Pain Symptom Manag. 2014;47:307–14.CrossRef
101.
Pinol V, Castells A. Percutaneous self-expanding metal stents versus endoscopic polyethylene endoprosthesis for treating malignant biliary obstruction: randomized clinical trial. Radiology. 2002;225:27–34.PubMedCrossRef
102.
Moss AC, Morris E, Leyden J, MacMathuna P. Do the benefits of metal stents justify the costs? A systematic review and meta-analysis of trials comparing endoscopic stents for malignant biliary obstruction. Eur J Gastroenterol Hepatol. 2007;19:1119–24.PubMedCrossRef
103.
Arkadopoulos N, Kyriazi MA, PapaniKolau IS, et al. Preoperative biliary drainage of severely jaundiced patients increases morbidity of pancreaticoduodenectomy: results of a case control study. World J Surg. 2014;38:2967–72.PubMedCrossRef
104.
Tol JAMG, van Hooft JE, Timmer R, Kubben FJ, van der Harst E, de Hingh IH, et al. Metal or plastic stents for preoperative biliary drainage in respectable pancreatic cancer. Gut Aug. 2015. (25 Published Online First).
105.
Van der Gaag NA, Rauws EAJ, van Eijck CHJ, Bruno MJ, van der Harst E, Kubben FJGM, et al. Preoperative biliary drainage for cancer of the head of the pancreas. N Engl J Med. 2010;362:129–37.PubMedCrossRef
106.
Lillemoe KD, Cameron JL, Hardacre JM, Sohn TA, Sauter PK, Coleman J, et al. Is prophylactic gastrojejunostomy indicated for unresectable periampullary cancer? A prospective randomized trial. Ann Surg. 1999;230:322–30.PubMedPubMedCentralCrossRef
107.
Rothlin MA, Schob O, Weber M. Laparoscopic gastro- and hepatico-jejunostomy for palliation of pancreatic cancer: a case controlled study. Surg Endosc. 1999;13:1065–9.PubMedCrossRef
108.
Van Hooft JE, Uitdehaag MJ, Bruno MJ, Timmer R, Siersema PD, Dijkgraaf MG, et al. Efficacy and safety of the new WallFlex enteral stent in palliative treatment of malignant gastric outlet obstruction (DUOFLEX study): a prospective multicenter study. Gastrointest Endosc. 2009;69:1059–66.PubMedCrossRef
109.
Hameed M, Hammeed H, Erdek M. Pain management in pancreatic cancer. Cancer. 2011;3:43–60.CrossRef
110.
Foley K. Pain syndromes and pharmacological management of pancreatic cancer pain. J Pain Symptom Manag. 1988;3:176–87.CrossRef
111.
Smith TJ, Staats PS, Deer T, Steams LJ, Rauck RL, Boortz-Mary RL, et al. Implantable drug delivery systems study group. Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival. J Clin Oncol. 2002;20:4040–9.PubMedCrossRef
112.
Mercadante S, Klepstad P, Kurita GP, Sjogren P, Giarrato A, European Palliative Care Research Collaborative (EPCRC). Sympathetic blocks for visceral cancer pain management: a systematic review and EAPC recommendations. Crit Rev Oncol Hematol. 2015;96:577–83.PubMedCrossRef
113.
Wyse JM, Carone M, Paquin SC. Randomized, double-blind, controlled trial of early endoscopic ultrasound-guided celiac plexus neurolysis to prevent pain progression in patients with newly diagnosed, painful, inoperable pancreatic cancer. J Clin Oncol. 2011;26:3541–6.CrossRef
114.
Arends J, Bodoky G, Bozzetti F, Fearon K, Muscaritoli M, Selga G, et al. ESPEN Guidelines on enteral nutrition: non-surgical oncology. Clin Nutr. 2006;25:245–59.PubMedCrossRef
115.
Bartel MJ, Asbun H, Stauffer J, Raimondo M, Bosaeus I, Bruera E, Faisinger RL, et al. Pancreatic exocrine insufficiency in pancreatic cancer: a review of the literature. Dig Liver Dis. 2015;47:1013–20.PubMedCrossRef
116.
Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Faisinger RL, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12(5):489–95.PubMedCrossRef
117.
Ozola Zalite I, Zykus R, Francisco González M, Saygili F, Pukitis A, Gaujoux S, et al. Influence of cachexia and sarcopenia on survival in pancreatic ductal adenocarcinoma: a systematic review. Pancreatology. 2015;15:19–24.PubMedCrossRef
118.
Loprinzi CL, Kugler JW, Sloan JA, Mailliard JA, Krook JE, Wilwerding MB, et al. Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia. J Clin Oncol. 1999;17:3299–306.PubMedCrossRef
119.
Lyman GH, Eckert L, Wang Y, Wang H, Cohen A. Venous thromboembolism risk in patients with cancer receiving chemotherapy: a real-world analysis. Oncologist. 2013;18:1321–9.PubMedPubMedCentralCrossRef
120.
Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111:4902–7.PubMedPubMedCentralCrossRef
121.
Pelzer U, Opitz B, Deutschinoff G, Stauch M, Reitzig PC, Hahnfeld S, et al. Efficacy of prophylactic low-molecular weight heparin for ambulatory patients with advanced pancreatic cancer: outcomes from the CONKO-004 Trial. J Clin Oncol. 2015;33:2028–34.PubMedCrossRef
122.
Maraveyas A, Waters J, Roy R, Fyfe D, Propper D, Lofts S, et al. Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer. Eur J Cancer. 2012;48:1283–92.PubMedCrossRef
123.
Lyman GH, Bohlke K, Falanga A. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Oncol Pract. 2015;11:e442–4.PubMedCrossRef
Metadata
Title
Consensus guidelines for diagnosis, treatment and follow-up of patients with pancreatic cancer in Spain
Authors
M. Hidalgo
R. Álvarez
J. Gallego
C. Guillén-Ponce
B. Laquente
T. Macarulla
A. Muñoz
M. Salgado
R. Vera
J. Adeva
I. Alés
S. Arévalo
J. Blázquez
A. Calsina
A. Carmona
E. de Madaria
R. Díaz
L. Díez
T. Fernández
B. G. de Paredes
M. E. Gallardo
I. González
O. Hernando
P. Jiménez
A. López
C. López
F. López-Ríos
E. Martín
J. Martínez
A. Martínez
J. Montans
R. Pazo
J. C. Plaza
I. Peiró
J. J. Reina
A. Sanjuanbenito
R. Yaya
Alfredo Carrato
Publication date
01-06-2017
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 6/2017
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-016-1594-x

Other articles of this Issue 6/2017

Clinical and Translational Oncology 6/2017 Go to the issue

Review Article

Exosomal microRNAs in liquid biopsies: future biomarkers for prostate cancer

Research Article

A long noncoding RNA UCA1 promotes proliferation and predicts poor prognosis in glioma

Research Article

Pembrolizumab for advanced melanoma: experience from the Spanish Expanded Access Program

Research Article

High early growth response 1 (EGR1) expression correlates with resistance to anti-EGFR treatment in vitro and with poorer outcome in metastatic colorectal cancer patients treated with cetuximab

Review Article

Treating patients with ALK-rearranged non-small-cell lung cancer: mechanisms of resistance and strategies to overcome it

Research Article

miR-26a-5p suppresses tumor metastasis by regulating EMT and is associated with prognosis in HCC
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits